The diagnosis of preeclampsia in pregnant women depends on assessing symptoms that do not reliably detect the disease, thereby delaying treatment decisions. GestVision Inc.'s test uses urine markers to rapidly detect preeclampsia at the point of care, which could give it broader utility than serum-based tests designed to confirm suspected diagnoses or detect a preeclampsia subtype.

Preeclampsia occurs in about 5% of pregnancies and can lead to life-threatening seizures. The condition is usually diagnosed in the second or third trimester when clinical symptoms of hypertension and proteinuria appear.